Dr. Michael A. Azrin, MD

Dr. Azrin practices at Uconn Health Carole and Ray Neag Comprehensive Cancer Center - HOPD in Farmington, Connecticut.

Dr. Azrin's NPI, 1558367938, was assigned on June 22, 2005. Dr. Azrin graduated from Washington University School of Medicine in 1985. Dr. Azrin holds Connecticut license 029036.

Dr. Azrin's primary practice is Uconn Health Carole and Ray Neag Comprehensive Cancer Center - HOPD, at 263 Farmington Ave, Farmington, CT 06030.

Dr. Azrin's primary practice is Uconn Health Carole and Ray Neag Comprehensive Cancer Center - HOPD in Farmington, Connecticut. Dr. Azrin is also affiliated with UConn John Dempsey Hospital. The medical group on file is UConn Medical Group.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Azrin practices, 2 sites in all. Vendor and product names are available with a free account.

Interventional cardiology is Dr. Azrin's primary specialty in the NPI Registry, under taxonomy code 207RI0011X. Dr. Azrin is licensed in Connecticut.

CMS data shows 48 Medicare services from Dr. Azrin across 3 procedure codes in 2024, for 61 Medicare patients. Medicare paid $9,628 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 61 Medicare patients who saw Dr. Azrin in 2024. The largest group is 75 to 84, with 28 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 25% are also on Medicaid. Their average risk score is 1.64, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Azrin's median patient age at 77, with 29% women.

In 2024, Dr. Azrin wrote 495 Medicare Part D claims for 69 patients. 89% of them were for generic drugs. CMS names the drug for 346 of them, across 10 drugs with 11 or more claims each, at $26,457 in total drug cost. In 2023, CMS named 348 claims across 12 drugs.

Dr. Azrin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 26 procedures of coronary angioplasty and stenting by Dr. Azrin, more than 60% of the clinicians it reports for that procedure.

Dmand AI links 26 papers to Dr. Azrin, published from 2012 to 2023. 2019 was the busiest year, with 5. The most frequent topics are Coronary Angiography, Cardiac Catheterization and Constriction, Pathologic. Dr. Azrin has published most often in Cardiovasc Revasc Med. Dr. Azrin's most frequent co-authors are Kalgi Modi, MD, Pavan Kumar Katikaneni, MD and Salman Khalid, MD.

Dmand AI links Dr. Azrin to 1 clinical trial. Conditions studied include Intermittent Claudication and Peripheral Arterial Disease. Open Payments lists research payments to Dr. Azrin that name 1 trial.

CMS Open Payments shows 74 general payments to Dr. Azrin from 15 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 49% of the total. Abbott Laboratories paid the most, $5,603. It also lists 2 research payments totaling $8,473 in 2016, naming 1 clinical trial.

Dr. Azrin graduated from Washington University School of Medicine in 1985.